OTCMKTS:USRM - US Stem Cell Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.0210 0.00 (0.00 %)
(As of 04/18/2019 01:01 PM ET)
Previous Close$0.0210
Today's Range$0.02 - $0.0210
52-Week Range$0.0106 - $0.0690
Volume22,039 shs
Average Volume745,642 shs
Market Capitalization$8.26 million
P/E RatioN/A
Dividend YieldN/A
U.S. Stem Cell, Inc. is a biotechnology company, which focuses on the discovery, development, and subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its product MyoCell, deals with the clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company was founded by Howard J. Leonhardt and Robert D. Lashinski on August 12, 1999 and is headquartered in Sunrise, FL.

Receive USRM News and Ratings via Email

Sign-up to receive the latest news and ratings for USRM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Current SymbolOTCMKTS:USRM
Previous SymbolNASDAQ:BHRT



Sales & Book Value

Annual Sales$6.70 million
Book Value($0.02) per share


Net Income$-2,160,000.00


Market Cap$8.26 million
Next Earnings Date5/8/2019 (Estimated)
OptionableNot Optionable

US Stem Cell (OTCMKTS:USRM) Frequently Asked Questions

What is US Stem Cell's stock symbol?

US Stem Cell trades on the OTCMKTS under the ticker symbol "USRM."

How were US Stem Cell's earnings last quarter?

US Stem Cell Inc (OTCMKTS:USRM) posted its quarterly earnings data on Wednesday, August, 8th. The company reported $0.00 earnings per share (EPS) for the quarter. The company had revenue of $1.82 million for the quarter. View US Stem Cell's Earnings History.

When is US Stem Cell's next earnings date?

US Stem Cell is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for US Stem Cell.

Has US Stem Cell been receiving favorable news coverage?

Press coverage about USRM stock has trended somewhat positive on Thursday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. US Stem Cell earned a coverage optimism score of 0.9 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future.

Who are some of US Stem Cell's key competitors?

What other stocks do shareholders of US Stem Cell own?

Who are US Stem Cell's key executives?

US Stem Cell's management team includes the folowing people:
  • Miguel Tomás, President, CEO, CFO & Director
  • Kristin C. Comella, Director & Chief Scientific Officer
  • Philip Posa, Senior Vice President-U.S. & International Sales

How do I buy shares of US Stem Cell?

Shares of USRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is US Stem Cell's stock price today?

One share of USRM stock can currently be purchased for approximately $0.0210.

How big of a company is US Stem Cell?

US Stem Cell has a market capitalization of $8.26 million and generates $6.70 million in revenue each year.

What is US Stem Cell's official website?

The official website for US Stem Cell is http://www.us-stemcell.com.

How can I contact US Stem Cell?

US Stem Cell's mailing address is 13794 NW 4TH STREET SUITE 212, SUNRISE FL, 33325. The company can be reached via phone at 954-835-1500 or via email at [email protected]

MarketBeat Community Rating for US Stem Cell (OTCMKTS USRM)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  72 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  127
MarketBeat's community ratings are surveys of what our community members think about US Stem Cell and other stocks. Vote "Outperform" if you believe USRM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe USRM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/18/2019 by MarketBeat.com Staff

Featured Article: What is intrinsic value?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel